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Drug Name: Aflibercept
Manufacturer: Regeneron, Bayer
Indication: Wet AMD
Formulation: Intravitreal injection
BLA
Drug Name: Aclidinium bromide
Manufacturer: Almirall, Forest
Indication: COPD
Formulation: Dry powder inhaler
Phase III
Aflibercept is under FDA review for the treatment 
of the neovascular form of age-related macular 
degeneration (wet AMD). By inhibiting vascular 
endothelial and placental growth factors, aflibercept 
may reduce the abnormal growth of blood vessels 
that damage the retina through blood and fluid leaks.
In two double-blind, non-inferiority, Phase III 
studies, VIEW 1 (N=1,217) and VIEW 2 (N=1,240), 
patients with wet AMD were randomized to 
intravitreal aflibercept 0.5 mg monthly, 2 mg monthly, 
or 2 mg every two months following three monthly 
loading doses, or intravitreal Lucentis® (ranibizumab) 
0.5 mg monthly for 12 months. The primary endpoint 
in both studies was the proportion of patients who 
maintained vision at 12 months, defined as the loss of 
fewer than 15 letters on the Early Treatment Diabetic 
Retinopathy Study eye chart. In VIEW 1, aflibercept 
0.5 mg monthly, 2 mg monthly, and 2 mg every two 
months showed non-inferiority to ranibizumab in 
the proportion of patients maintaining vision (95.9, 
95.1, and 95.1 versus 94.4 percent, respectively, P 
value not reported). Similar results were also seen 
in VIEW 2 between the aflibercept and ranibizumab 
groups (96.3, 95.6, and 95.6 versus 94.4 percent, 
respectively, P value not reported). The incidence of 
side effects was similar among all treatment groups.
An FDA decision on the Biologics License 
Application (BLA) for the indication of wet AMD is 
expected on Aug. 20, 2011. If approved, aflibercept 
may offer less frequent dosing without compromising 
efficacy compared to ranibizumab for this indication.
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Aclidinium bromide, a long-acting, inhaled 
anticholinergic bronchodilator, is an antagonist at 
the M2 and M3 muscarinic receptors. It is being 
studied for the treatment of chronic obstructive 
pulmonary disease (COPD). 
Three Phase III, randomized, double-blind trials 
compared aclidinium bromide 200 μg and 400 μg 
twice daily to placebo in patients with moderate to 
severe COPD. In each study, the primary endpoint 
was the change in morning trough forced expiratory 
volume in one second (FEV1), from baseline to week 
12. In the ATTAIN study (N=828), aclidinium bromide 
at doses of 200 μg and 400 μg produced statistically 
significant increases in trough FEV1 at week 12 
versus placebo (77 and 105 mL, respectively, 
P≤0.0001). In the ACCORD COPD I study (N=561), 
similar increases in trough FEV1 over placebo were 
seen with 200 μg and 400 μg of aclidinium bromide 
(86 and 124 mL, respectively, P<0.0001). However, 
in the ACCORD COPD II study (N=544), the increase 
in trough FEV1 versus placebo (72 mL, P=0.001), for 
the anticipated therapeutic dose of 400 μg, was less 
than that of the other two Phase III trials. The most 
common adverse effects were COPD exacerbation, 
dyspnea, headache, and nasopharyngitis.
Due to its favorable effects on trough FEV1 
and low incidence of anticholinergic side effects, 
aclidinium bromide may compete with Spiriva® 
(tiotropium bromide). However, once-daily 
tiotropium bromide maintains an advantage in 
dosing frequency. A New Drug Application (NDA) 
submission is planned for mid-2011.
Promising New Agents
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Promising New Agents
Non-Specialty Specialty
Drug Name: Dimethyl fumarate
Manufacturer: Biogen Idec
Indication: RRMS
Formulation: Oral capsule
Phase III
Name: Elvitegravir
Manufacturer: Gilead Sciences
Indication: HIV-1 infection
Formulation: Oral tablet
Name: Laquinimod
Manufacturer: Teva 
Indication: RRMS
Formulation: Oral capsule
Phase III 
Dimethyl fumarate is an oral agent 
being studied for the treatment of 
relapsing-remitting multiple sclerosis 
(RRMS). It produces anti-inflammatory 
effects by suppressing nuclear factor 
κB-dependent transcription, while also 
reducing oxidative neuronal death and 
maintaining myelin integrity.
In DEFINE, a two-year, double-blind, 
randomized, Phase III study, dimethyl 
fumarate 240 mg two or three times 
daily was compared to placebo in over 
1,200 patients with RRMS. Compared to 
placebo, treatment with either dose of 
dimethyl fumarate significantly reduced 
the proportion of patients who relapsed 
at two years (P<0.0001), the primary 
endpoint. In the twice-daily group, the 
reductions in the primary endpoint, the 
annualized relapse rate (ARR), and the 
progression of disability were 49, 53, and 
38 percent, respectively, compared to 
placebo (P values not reported). Similar 
reductions were seen in the three-times-
daily group. According to preliminary 
data from DEFINE, dimethyl fumarate 
has demonstrated a favorable safety and 
tolerability profile.
The increased dosing frequency 
with dimethyl fumarate may be a 
disadvantage compared to once-daily 
oral Gilenya® (fingolimod). Additionally, 
fingolimod may produce greater 
reduction in ARR (54 to 60 percent versus 
placebo) than what has been shown thus 
far with dimethyl fumarate. An NDA 
submission is planned by the end of 2011.
Laquinimod is a novel, once-daily 
oral immunomodulator being studied for 
the treatment of RRMS. Although the 
exact mechanism of action is unknown, 
laquinimod is thought to reduce the 
infiltration of immune cells into the 
central nervous system and to change 
the cytokine balance in favor of an anti-
inflammatory T helper-2 lymphocyte 
profile. These effects may reduce myelin 
destruction and axonal damage, which are 
associated with disability in RRMS.
Laquinimod 0.6 mg once daily was 
compared to placebo in ALLEGRO, a 
two-year, randomized, double-blind, 
Phase III study (N=1,106) of patients with 
RRMS. Compared to placebo, patients 
treated with laquinimod experienced a 
23 percent reduction in ARR (P=0.0024), 
the primary endpoint in the study. 
Compared to placebo, treatment with 
laquinimod was also associated with a 36 
percent reduction in the risk of confirmed 
disability progression, as measured by 
the Expanded Disability Status Scale 
(P=0.0122), as well as a 33 percent 
reduction in the progression of brain 
atrophy (P<0.0001). The most common 
adverse effects included headache, 
nasopharyngitis, and back pain. Although 
liver enzyme elevations occurred more 
frequently with laquinimod than placebo, 
they were asymptomatic and reversible.
While the reduction in ARR versus 
placebo seen with laquinimod (23 
percent) may be lower than that seen 
with fingolimod (54 to 60 percent), this 
agent may become another once-daily 
treatment option for RRMS. An NDA 
submission is planned by the end of 2011.
Elvitegravir is an oral integrase 
inhibitor being studied for the treatment 
of human immunodeficiency virus type 1 
(HIV-1) infection. It interferes with HIV 
replication by blocking the integration of 
the virus into the human genome. 
A Phase III, randomized, double-
blind, non-inferiority trial compared 
elvitegravir 150 mg daily (N=351) to 
Isentress® (raltegravir) 400 mg twice daily 
(N=351), both added to a ritonavir-boosted 
protease inhibitor and a second antiviral 
agent, in treatment-experienced adults 
with an HIV viral load of at least 1,000 
copies/mL. The proportion of patients 
achieving and maintaining a viral load of 
less than 50 copies/mL through week 48, 
the primary endpoint, was similar between 
the elvitegravir and raltegravir treatment 
groups (59 versus 57.8 percent, 95 percent 
CI for the difference: -6 to 8.2 percent), 
meeting pre-defined criterion for non-
inferiority. The frequency of severe and 
life-threatening adverse events was similar 
in the two groups.
The once-daily dosing of elvitegravir 
may be an advantage over twice-daily 
raltegravir, the only FDA-approved 
integrase inhibitor. Elvitegravir, combined 
with Truvada® (emtricitabine/tenofovir) 
and cobicistat, an investigational boosting 
agent with no anti-HIV activity, is in Phase 
III trials. This new tablet formulation, 
called Quad, may become the second 
complete once-daily regimen available. 
NDA submissions for Quad and elvitegravir 
are planned for the first half of 2012.
Phase III
Promising New Agents
Non-Specialty Specialty
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Drug Name: Tofacitinib
Manufacturer: Pfizer
Indication: Rheumatoid arthritis
Formulation: Oral tablet
Phase III
Name: Mipomersen
Manufacturer: Genzyme, Isis 
Indication: Hypercholesterolemia
Formulation: Subcutaneous injection
Phase III
Name: Lixisenatide
Manufacturer: Zealand, Sanofi-Aventis
Indication: Type 2 diabetes mellitus
Formulation: Subcutaneous injection
Phase III
Tofacitinib is an oral Janus kinase 
(JAK) inhibitor being studied for the 
treatment of rheumatoid arthritis 
(RA). Unlike current RA therapies, 
which target extracellular cytokines, 
tofacitinib modulates the intracellular 
JAK pathway to improve inflammatory 
immune response in patients with RA.
In ORAL Sync, a 12-month Phase III 
study (N=792), patients with moderately 
to severely active RA were randomized 
to tofacitinib 5 mg or 10 mg twice 
daily or placebo, both as an adjunct to 
existing non-biologic disease-modifying 
antirheumatic drug (DMARD) therapy. A 
greater proportion of patients receiving 
tofacitinib 5 mg or 10 mg achieved a 20 
percent improvement in the American 
College of Rheumatology criteria at six 
months compared to placebo (52.7 and 
58.3 versus 31.2 percent, respectively, 
P<0.0001 for both). Moreover, 11 and 
14.8 percent of patients treated with 
tofacitinib 5 mg and 10 mg, respectively, 
were considered to be in remission at 
six months (Disease Activity Score 28-4 
[DAS28-4] of less than 2.6), compared 
to 2.7 percent of patients in the 
placebo group (P<0.001 and P<0.0001, 
respectively). Infection was the most 
commonly reported adverse event. Four 
deaths occurred in the tofacitinib groups; 
one was due to respiratory failure found 
to be related to tofacitinib.
Tofacitinib, with its new mechanism 
of action, may be combined with 
traditional DMARDs to offer RA patients 
another treatment option before starting 
injectable biologic DMARDs. An NDA 
submission is planned by the end of 2011.
Lyxumia® (lixisenatide), a once-daily 
glucagon-like peptide-1 (GLP-1) agonist, is 
being studied for the treatment of type 2 
diabetes mellitus. 
In three randomized, double-blind, 
placebo-controlled, Phase III trials in the 
GetGoal program, lixisenatide reduced 
HbA1c when used as monotherapy in the 
12-week -MONO (N=361) trial, as an add-
on to a sulfonylurea (SU) (with or without 
metformin) in the 24-week -S (N=859) trial, 
and as an add-on to basal insulin (with 
or without a SU) in the 24-week -L-ASIA 
(N=311) trial (P<0.0001 versus placebo for 
all). In the GetGoal-S study, treatment 
with lixisenatide was also associated 
with weight loss compared to placebo 
(P<0.0001).
When added to metformin in the 24-
week, Phase III GetGoal-X trial (N=639), 
lixisenatide met the primary endpoint 
of non-inferiority in HbA1c reduction 
from baseline compared to twice-daily 
exenatide, with fewer patients 
reporting symptomatic hypoglycemia 
(2.5 versus 7.9 percent, P<0.05). 
In an indirect comparison, once-
daily Victoza® (liraglutide) was shown 
to produce greater reductions in HbA1c 
compared to lixisenatide when used 
as monotherapy (0.84 to 1.14 percent 
versus 0.73 to 0.85 percent). Without 
direct comparisons, it is unclear if the 
differences in pharmacokinetic profiles 
among the various GLP-1 agonists will 
lead to any clinical advantages. An NDA 
submission is planned for 2012.
Mipomersen is being studied for the 
treatment of hypercholesterolemia. It 
inhibits the synthesis of apolipoprotein 
B, the structural core of all atherogenic 
lipids, thereby decreasing the formation of 
low-density lipoprotein (LDL).
In a 26-week trial, 158 patients with 
high risk of coronary heart disease (CHD), 
who were receiving a maximally tolerated 
dose of a statin with or without other 
lipid-lowering therapy, and who had an 
LDL of at least 100 mg/dL and triglycerides 
less than 200 mg/dL, were randomized 
to add-on mipomersen 200 mg weekly or 
placebo. The primary endpoint, change 
from baseline in LDL levels at two weeks 
after the last dose, was greater with 
mipomersen than placebo (37 versus 5 
percent reduction, P<0.001). A second 26-
week trial included 58 patients with severe 
hypercholesterolemia who were on a 
maximally tolerated statin and at least one 
other lipid-lowering therapy, with LDL of 
at least 300 mg/dL or 200 mg/dL with CHD. 
Add-on mipomersen produced 36 percent 
reduction in LDL versus 13 percent increase 
seen with placebo (P<0.001). Common 
adverse events included elevated alanine 
aminotransferase levels, flu-like symptoms, 
and injection site reactions.
The results of these Phase III trials 
are planned to be submitted in the initial 
NDA, expected in the second half of 2011, 
for the indication of homozygous familial 
hypercholesterolemia. Mipomersen may be 
used as an add-on to lipid-lowering agents  
in patients who are difficult to get to goal.
 Projected Generic Entry*
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Lucentis® (ranibizumab)
Two Phase III trials compared ranibizumab to placebo 
in patients with diabetic macular edema (DME). The 
primary endpoint was the proportion of patients who 
were able to read at least 15 more letters on an eye 
chart at 24 months versus baseline. In the RIDE study 
(N=382), 33.6 and 45.7 percent of patients treated 
with monthly injections of ranibizumab 0.3 mg and 
0.5 mg, respectively, achieved the primary endpoint, 
versus 12.3 percent with placebo. The RISE study 
also met the same endpoint. Ranibizumab, approved 
for the treatment of wet AMD and macular edema 
following retinal vein occlusion, would be the first 
FDA-approved medication for DME.
Information available at www.gene.com. 
Arcalyst® (rilonacept)
Three Phase III trials studied rilonacept for reducing 
flares in gout patients currently taking or newly 
starting uric acid-lowering therapy. In the PRE-SURGE 
2 study (N=248), rilonacept was self-administered 
subcutaneously with a loading dose of 160 mg 
followed by 80 mg weekly, or 320 mg followed by 160 
mg weekly. At 16 weeks, both doses of rilonacept 
reduced the mean number of gout flares by 72 
percent versus placebo (P<0.0001). A supplemental 
BLA for this indication is planned for mid-2011.   
Information available at www.regeneron.com.
• Nasacort® AQ (triamcinolone) 
      6/2011
•   Levaquin® (levofloxacin) 
 6/2011
 
• Uroxatral® (alfuzosin ER) 
 7/2011    
• Anzemet® (dolasetron) 
 7/2011   
• Zyprexa® and Zyprexa®
      Zydis® (olanzapine)     
      10/2011
• Symbyax® (olanzapine/fluoxetine)   
      10/2011
• Malarone® (atovaquone/proguanil)
      10/2011
• Lipitor® (atorvastatin) 
 11/2011
• Caduet® (amlodipine/atorvastatin)  
 11/2011
Boceprevir (VictrelisTM) and telaprevir 
(IncivekTM)
In May 2011, two oral hepatitis C virus (HCV) 
NS3/4A protease inhibitors, boceprevir and 
telaprevir, received FDA approval for the 
treatment of HCV genotype 1 infection in 
combination with peginterferon alfa and 
ribavirin. The agents have shown increased rates 
of sustained virological response compared to 
the current standard of care and may shorten 
duration of HCV therapy from 48 to 24 or 28 
weeks for some patients. Both were approved for 
three-times-daily administration in treatment-
naïve and treatment-experienced patients. 
Cladribine (Movectro®)
On March 2, 2011, Merck Serono announced it 
had received a complete response letter (CRL) 
from the FDA regarding the NDA for cladribine 
for the treatment of RRMS. While the CRL 
indicated that the evidence from the CLARITY 
trial supported the effectiveness of cladribine 
in RRMS, it included a request for further 
information on the safety, risks, and overall 
benefit-risk profile. Merck Serono plans to 
request a meeting with the FDA to determine if 
data from ongoing studies, CLARITY EXTENSION, 
ORACLE MS, and ONWARD, expected in 2011 
and 2012, or safety information from already 
completed studies, can address FDA concerns.
Naltrexone SR/bupropion SR (Contrave®)
Orexigen and Takeda received a CRL from the 
FDA on Jan. 31, 2011, regarding the NDA for a 
sustained-release (SR) formulation of naltrexone 
and bupropion for the treatment of obesity. 
The CRL requested a randomized, double-blind, 
placebo-controlled trial of sufficient size and 
duration to show that the risk of cardiovascular 
events does not adversely impact the drug’s 
benefit-risk profile. The trial subsequently 
proposed by Orexigen was rejected by the 
Division of Metabolic and Endocrinologic 
Products as inadequate. In response, Orexigen 
plans to hold clinical development for its U.S. 
obesity programs and to appeal this rejection.
*Dates are estimates, current as of 6/15/11, and are subject to change due to any patent litigation or additional patents.
• Solodyn® (minocycline ER)† 
 11/2011
• Tazorac® (tazarotene) 
 12/2011
• Combivir® (lamivudine/ 
 zidovudine)  
 12/2011
•   Entocort® EC (budesonide) 
 2/2012
•   Lexapro® (escitalopram) 
 3/2012
•   Seroquel® (quetiapine) 
 3/2012
•   Gabitril® (tiagabine) 
 3/2012
•   Avandia® (rosiglitazone),    
      Avandamet® (rosiglitazone/      
      metformin), Avandaryl®   
       (rosiglitazone/glimepiride) 
 3/2012
†45, 90 and 135 mg extended-release tablets.
 CNS
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Agents in Clinical Development
Pipeline Research
Phase I - 32%
Phase II - 38%
Phase III - 21%
NDA/BLA - 9%
Oncology - 16%
Infectious Disease - 15%
CNS - 13%
Pain and 
Inflammation - 9%
Cardiology - 8%
Metabolic - 6%
Respiratory - 5%
Other - 28% 
Acura, King
Treatment of moderate 
to severe pain
Oxycodone IR  
abuse-resistant tablet
Merck, Santen Reduction of  
elevated IOP
Sumatriptan transdermal 
patch (Zelrix™)
NuPathe PDUFA date 8/29/2011
Zolpidem sublingual  
tablet (Intermezzo®)
Transcept, Purdue
Mirabegron
Indacaterol (Arcapta™ 
Neohaler™)
Novartis
Dapagliflozin Type 2 diabetes PDUFA date 10/28/2011
Clobazam (Onfi™) 
Oral calcitonin
Middle of the night 
awakenings
AstraZeneca,  
Bristol-Myers Squibb    
Rivaroxaban (Xarelto®) Johnson & Johnson, 
Bayer
AF,  
prevention of VTE 
NDA for use in AF and response 
to CRL for VTE prevention 
submitted in 1/2011 
Acute treatment 
of migraine
NDA submitted 5/2011
Astellas
NDA submission planned 
for fourth quarter of 2011
Lundbeck
NDA accepted 3/2011
Eisai
Adjunct treatment of 
refractory partial  
onset seizures
Oxycodone ER  
abuse-resistant capsule 
(Remoxy®)
Treatment of moderate 
to severe pain
Pain Therapeutics, 
Pfizer
PDUFA date 6/23/2011 
PDUFA date 7/14/2011
PDUFA date 6/17/2011
Table Abbreviations: ACS = acute coronary syndrome, AF = atrial fibrillation, 
COPD = chronic obstructive pulmonary disease, CRL = complete response 
letter, ER = extended release, IOP = intraocular pressure, IR = immediate 
release, IV = intravenous, NDA = new drug application, PDUFA = Prescription 
Drug User Fee Act, SC = subcutaneous, VTE = venous thromboembolism
ND
A/
BL
A Phase III
Pha
se I
I
On
co
lo
gy
CNSPain/Infl.
Ca
rd
io
.
Me
ta
bo
licResp.
Inf. Dis
ease
Phase I
Other
COPD
Perampanel
NDA submission planned 
for second quarter of 2011
Lennox-Gastaut  
syndrome
Dihydroergotamine 
inhalation (Levadex®)
Apixaban (Eliquis®)
Bristol-Myers Squibb, 
Pfizer
AF
Treatment of  
postmenopausal  
osteoporosis
Tarsa
AstraZeneca PDUFA date 7/20/2011Ticagrelor (Brilinta™)
NDA submission planned 
for second half of 2011
FDA response expected  
in 7/2011
Treatment of ACS
Treatment of  
migraine
FDA response expected  
in 10/2011
MAP                        
Pharmaceuticals
Treatment of  
overactive bladder
NDA submission planned 
for second half of 2011
Tafluprost opthalmic  
solution (Saflutan®)
Anemia in chronic  
renal failure
Peginesatide*  
(SC, IV)
Affymax, Takeda NDA submitted 5/2011
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Who We Are and What We Do
The University of Massachusetts Medical School’s Clinical Pharmacy Services is a comprehensive 
prescription drug management program developed in 1999 as part of the Medical School’s Commonwealth 
Medicine division, primarily to provide drug utilization review for Massachusetts Medicaid.  Today, we bring    
exceptional depth and experience in the development and implementation of unique, client-customized, 
managed care-related clinical pharmacy functions including, but not limited to, evidence-based formulary 
support, pharmacoeconomic modeling, drug utilization review, medication therapy management, clinical 
call center support, and provider/patient education. PIPELINE TRxENDS is an educational resource produced 
twice yearly to deliver critical information at the highest level of quality to our clients.  We hope that you 
find this resource of value, and we welcome your suggestions for improvement.
